+ was present in 71% of the patients. Thymic hyperplasia was present in 5.93% of the patients, while 1.48% had thymoma. S������ treatment was effective in the majority of the p�������. Ocular type MG was common in this ������ of p�������. The incidence and mortality of ���������� ������ were low, the presence of concurrent thymoma was rare and ���� a limited number of �������� ��v���p�� �������g���� sequelae.
Introduction
M��������� g��v�� (MG) �� �� ���������� ������� p�������� �������� b� ��� ����-������������� ����p��� ����b��� (AchR-Ab), which is associated with a variety of immune ��������� ��� ������ �� neuromuscular junctions (1, 2) . MG is characterized by skeletal muscle weakness, �� p���s of �� ��� ������ b��� following continuous repetitive motion, fatigability and fluctuating levels of muscle weakness, as well as ����� ���p����, ��������g ��p��p��, p����� and difficulties in ����������� ��� swallowing. It was previously demonstrated that genetic factors play an important role in the pathogenesis of MG (3) . In addition, viral or bacterial infections, such as p����v���� ��� Escherichia coli, ��� b� ��v��v�� �� ��� p����-genesis of MG (4, 5) . However, ����� �� �� �v������ ���������g a definit�ve MG pathogenesis. A���-�������������� ���g�, ���-specific immunosuppressive agents, thymectomy and p�����p������� ��� ��������� the main treatment options (6) (7) (8) . MG �� ���� ������ ����g Chinese children, who �x��b�� significantly different clinical characteristics ���p���� �� ����� �b���v�� �� adults. The ��� of this study was to analyze the clinical characteristics, classification and treatment of MG �� �������� ��� understand the prognosis through follow-up, in ����� �� ��������� ��� �p����� ��������� �p����� ��� ��p��v� ��� p�������' quality of life. In addition, we p������ ��� ������-sions drawn from the age-related clinical ���������������, treatment and prognosis.
Materials and methods
Experimental subjects. A total of 135 �������� ���g����� with MG, who were admitted to the Children's Hospital of Zhengzhou between January, 2008 and January, 2014, were included in this study. T�� p������� �������� 57 ����� and 78 females. The �g� �� ����� ���g�� between 4 months ��� 15 years, with an average age at onset of 3 years ��� 2 months. Three patients were �g�� <1 year, 65 were �g�� 4 months-3 years, 41 were �g�� 4-7 years, 20 were �g�� 8-12 years and 6 patients were �g�� 13-15 years. The age at the time of the doctor's visit ���g�� between 4 months ��� 15 years. A total of 81 p������� were newly diagnosed and 54 received irregular treatment or �xp�������� ���������� following treatment.
This study was conducted in accordance with the p���-ciples of the Declaration of Helsinki ��� �����v�� �pp��v�� from the Ethics Committee of ��� P�k��g U��v������ F���� Hospital. Written informed consent was obtained from all ��� p������p���� �� ����� ��g�� ����������.
Diagnostic criteria and classification. The following clinical symptoms were considered indicative of MG: muscle fatigue; muscle weakness mitigated in the morning and worsening �� ��� �v����g; ��� p��g�����v� ������ weak���� following ���������� �� ��p����� ������������, ����g���� with ���� �� cholinesterase inhibitor use.
Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis
T�� ���g����� �� confirmed with a positive result on one of the following tests (9) : fatigue test or sulfuric acid neostigmine test (every 0.025-0.05 mg/kg, no improved muscle weakness after 15-30 min, restitution after 1.5 h); ��p�����v� ���v� ����������� frequency test (low-frequency repetitive stimulation of muscle ������ p�������� ��p������, ���������g ����������� >10%); or positive determination of serum anti-AchR antibody.
The MG classification was determined using the modified Osserman method as follows: �ype I (ocular type MG; OMG) with only extraocular muscle involvement, including type Ia (p�����) ��� ��p� Ib (ptosis and eye fixation); ��p� II (g������ ��p� MG; GMG) ��������g ��p� II� (��� ��� ���b ������ weakness) ��� ��p� IIb (general weakness �����g ����������� or swallowing and dysarthria); �ype III (fulminating type) with sudden weakness and myasthenic crisis; �ype IV (flaccid type), which p��g������ from ��p� I �� II ��� p��k� �� 2-3 �����; ��� �ype V (amyotrophic type) (4).
Methods. T�� �������� ���������������, affiliated examinations, treatment and prognosis of the patients were retrospectively analyzed and prospectively followed up.
Statistical analysis. Data analysis was performed using SPSS 14.0 software (SPSS I��., Chicago, IL, USA). Continuous ���� ��� �xp������ �� ����� ± �������� ��v������ �� ������� and maximum. Enumeration data are expressed as the number of patients and frequency. Groups based on the enumeration data are expressed using the number of patients and percentage of patients within each group. The comparisons among the enumeration data groups were performed using Chi-square ����� �� F�����'s exact tests. P<0.05 was considered to �������� � statistically significant difference.
Results
Clinical manifestations and classification. T�� ��������� ����-tion was <1 month in 55 patients, 1-3 months in 29 patients, 4-6 months in 12 patients, 7-12 months in 7 patients and 1-13 years in 32 patients. The majority of ��� patients with a ������� ������ of ≤6 months were newly diagnosed p�������, while the majority of ��� patients with a disease course of >6 ������ �����v�� ����g���� ��������� �� �xp�������� ����p�� following treatment. All the patients experienced manifestations ��v��v��g �������� ������ weakness during hospitalization: only 61 patients (45.2%) had ptosis; 54 patients (40.0%) had a combination of p����� and eye movement disorders; 14 patients ��� ������ ���p���� with associated limb weakness; 4 patients had a combination of bulbar muscle involvement, such as facial, ���g��, ������ ��� ����������� muscle weakness; and 2 patients had respiratory muscle involvement. Type I was present in 115 patients (85.2%), type II in 18 patients, type III in 2 patients (1.5%) and none of the patients had type IV or V (T�b�� I).
A 12-year-old female patient ��v���p�� ��p������������ following multiple disease recurrences. A 2.3-year-old female patient also had selective IgA deficiency. A total of 6 p������� �xp�������� a myasthenic crisis during the course of ��� disease, including 4 patients who underwent ventilator-assisted ���p������� therapy and 2 patients who ������b�� �� ��v��� pulmonary infection. An 18-year-old patient was misdiagnosed with muscular dystrophy; 4 patients were misdiagnosed with oculomotor nerve palsy, including 1 patient that was misdiagnosed for 4 years; 5 patients were misdiagnosed with G�������-B���é syndrome; and 1 patient was misdiagnosed with idiopathic epilepsy. Two patients only �x��b���� ���b-g����� ������ weakness, with an early misdiagnosis of psychogenic �������; and 2 patients were misdiagnosed with brain stem encephalitis. These patients were ���������� ���g����� ����g ����������g��p�� (EMG), ����� A��R-Ab ��������� ��� response to treatment.
Serum antibody. Serum AchR-Ab (Beijing-Hui Bogosian Biotechnology Co., Ltd. Beijing, China), anti-ryanodine ����p��� ������� ������� ������� ����b��� (R�R-Ab) (Shanghaikamaishu Biotechnology Co., Ltd., USA) and anticatenin antibody (Titin-Ab) (Shanghai Chemical Reagent Co., Ltd., Shanghai, China) were detected by ELISA and monitored during follow-up. S���� A��R-Ab was positive in 43 (40.19%) of the 107 primarily diagnosed patients and the positiv��� ���� was not significantly different among the clinical subtypes. Of the 28 primarily diagnosed patients in whom serum RyR-Ab was detected, 3 patients (10.71%) were ���� p�����v� for AchR-Ab Serum Titin-Ab was detected in 30 patients and 12 patients (40%) tested positive for both Titin-Ab and AchR-Ab. Computed tomography (CT) did not reveal thymoma in 9 of these patients and chest radiography was normal in 3 patients who did not undergo chest CT. Of ��� 18 p������� with negative Titin-Ab, 7 were p�����v� for A��R-Ab, whereas the remaining 11 patients were negative. Following ��������� for 6-24 months, 24 patients underwent dynamic follow-up of serum AchR-Ab and 9 of the 17 patients (53%) who were ��������� ��g���v� for A��R-Ab were found to be p�����v�; �� 2 of these patients, AchR-Ab remained positive from the end of treatment to clinical recovery during the follow-up. Of ��� 7 patients with positive AchR-Ab, 4 had negative AchR-Ab with symptomatic remission.
EMG. EMG (Model ZET-100; Shanghai Zhong Ren Electronic Instrument Co., Ltd.) was conducted �� 79 patients, with routine inspection of the fac���, �����, ������ ��� ������ p������� nerves; the skin over the muscles was routinely disinfected and the needle poles were quickly inserted. The pin position was selected as the center of the abdominal muscle or movement points and a 1 or 2 needle electrode was inserted into every muscle. The different (upper, middle, or lower) muscle insertion sites were selected when the parameters of the motor unit potential were determined. The repetitive nerve stimulation frequency test of the 30 patients (37.97%) �x��b���� �������-����, whereas none of the ocular patients �x��b���� p���p����� nerve attenuation.
Immunological parameters. A� ��g���� the 63 patients who underwent immunoglobulin and the 101 who underwent CD ������ �����, ��� IgG, IgA and IgM results were all normal, 1 p������ �x��b���� decreased IgA and 71% of the patients had CD series count abnormalities, with the majority �xp������g decreased CD4 + ��� CD8 + ��� ���� p������� �xp������g ��������� CD19 + (T�b�� I).
Imaging. R������ �����g��p��� �x��������� of the anteroposterior chest was performed �� 131 patients and 57 patients underwent simultaneous single-slice spiral CT of the ������; 8 patients (6.11%) �x��b���� ������ ��p��p����� ��� 2 p������� (1.5%) had thymoma that was pathologically diagnosed, without Titin-Ab detection.
Other tests. Following b���� b�����������, ������ ������ and thyroid function tests, 1 patient had hyperthyroidism with positive thyroglobulin and anti-thyroid peroxidase antibodies.
The echocardiography results of all ��� patients were normal.
Treat ment. Oral pyridinium bromide neostigmine (5-7 mg̸kg̸day, 3 times/day) was administered to 39 patients for 6 months to 1 year, depending on the condition. Oral prednisone was administered to 26 patients, with transitional reduction: the initial 1.5-2 mg̸kg̸day was gradually reduced to 7.5-10 mg every morning and with optimal symptom control (4-6 weeks later), the therapy was maintained for 1-2 years. Seven patients were treated with pyridinium bromide neostigmine combined with prednisone that was transitionally reduced; for the 61 patients treated with methylprednisolone pulse therapy at a dose of 15-20 mg̸kg̸day, each week-long course consisted of a continuous administration for 3 days and no treatment for 4 days for 1-3 courses, followed by 1.5-2 �g̸kg̸��� oral prednisone, which was reduced after 4-6 weeks and followed by a reduction of 0.5 mg/kg oral prednisolone every two weeks in transitional ����������. After it was decreased to 0.5 mg/kg/day it was maintained at that concentration for a period of 1-2 years. Two patients were routinely administered prednisone for 1-2 ����� p����p�����v��� following thymectomy. In addition, 10 patients were treated with 400 mg̸kg̸day intravenous gamma globulin (IVIG) due to repeated ���������� of the disease, once a day for 5 days. A total of 9 p������� �����v�� ������p���� A, �������p���� ��� ����� ��������pp�����v� agents. The duration of improved muscle weakness, duration of ��x���� effect and recurrence (e.g., symptoms ���pp�����g following discontinuation of the drug) were monitored during the follow-up for inpatients and outpatients.
Regarding the four ��p�� of treatment (based on the initial ��������� p��g���), 39 p������� were classified �� ��� ���g�� p��������� b������ ������g���� g���p, 26 p������� �� ��� transitional reduction of oral prednisone group, 7 patients to the pyridinium bromide neostigmine in combination with reduction of prednisone g���p ��� 61 p������� �� ��� ����-ylprednisolone pulse therapy group. The mean treatment onset time was 13 (10-17), 11 (4-15), 8 (1-12) and 2 (1-6) ����, respectively. The mean duration of ��� maximum effect was 74 (23-212), 52 (19-174), 48 (7-125) and 18 (3-54) ����, ���p��-tively, with no significant difference� among the subtypes. The follow-up of the treatment lasted for 2-15 years (until January, 2010), during which time 29 patients were lost to follow-up, with the remaining 106 MG p������� ���p�����g ��� follow-up. During the treatment, relapse occurred 1-2 times in 43 patients, 3-5 times in 10 patients and >5 times in 1 patient; the onset of relapse occurred within 2 years for 84.6% of the patients. The frequency of relapse was not significantly different between the single pyridinium bromide neostigmine ��� ��� ������� groups, but the lower rate of recurrence in the ������� treatment group was statistically significant (T�b�� II). In the 10 patients who were administered IVIG due to ��p����� ����������, their condition improved markedly in the first 10-15 days following the injection. D�� �� frequent relapses or steroid dependence/resistance, 2 p������� �����v�� ���������� azathioprine and 1 patient was switched to cyclosporin A treatment due to bone marrow suppression. A total of 9 patients were administered cyclo�p���� A ��� 1 of these patients was switched to sulfur azathioprine due to suboptimal efficacy.
Adverse reactions. A�� ��� ����� ��v���� ��������� ���� ��v��-�p�� in patients who underwent ������� �����p� ����� ��v��v�� different degrees of Cushing's syndrome, weight gain, hypertension (n=1) and weakness exacerbation (n=2). Patients who were administered pyridinium bromide neostigmine ���b���� with steroid �����p� �x��b���� �� ����� �x����b����� of weakness. Up�� ���p��� ��p��v�����, ��� ������� ���� was reduced. During the maintenance period, the majority of ��� p������� �x��b���� no other long-term adverse effects, ���� �� ��v��� infections, fractures, abscess formation �� g�������-�������� ��������g�.
Follow-up.
The longest follow-up period was 15 years �� 1 patient, who �� ��������� 27 years old, without symptoms of muscle weakness. A total of 4 patients experienced sequelae in the form of ������ ��v����� ��������� ��� 2 p������� ������b�� �� ��� �������.
Discussion
MG is an acquired autoimmune neuromuscular transmission disorder. The pathophysiology involves the production of A��R-Ab and the inhibition of A��R, �������g the number of functional AchR in the neuromuscular junction, which ����� �� �� �b������ ������� �� ��� ����� ���p���� ���b���� potential. Studies conducted in Europe and the United States have reported a prevalence of 14-1.5/1.0x10 5 , with �� �������� MG onset during childhood (10-15%) (10) . However, a recent ����� ��������� �� C���� ��������� ���� the onset of MG in children is not rare in China (11), with ������� ����� �� ����� �� Japan (12) , indicating that pediatric MG is relatively common in Asia. The results of the present study are consistent with ����� �v����b�� �� ��� ���������� ��� ������������ a relatively early age at onset (50.3% of the patients were �g�� <3 years), with a ���g������ ��g��� ���� ����g females (56.3%), ������ relapse (50.9%) and a ��g��� ����p�� ���� within the first 2 years. A ��g��� ���b�� of children with MG in European countries progress to GMG within 2 years. Research in Japan has indicated that 75% of patients with OMG had recessive GMG (13), i.e., no clinical ���p���� were present, b�� EMG �������� ��p�����v� ���v� stimulation frequency attenuation in other nerves in addition to the facial nerve �� p������� who were diagnosed with latent GMG. Our patients rarely progressed to GMG and EMG did ��� ��gg��� �� ����������� p��������� �� ����� �������g���� examinations of children with OMG (rare recessive GMG). However, detailed history, increased number of fatigue test� and EMG sites and long-term follow-up of ��� p������� ������ be performed in order to increase the accuracy of typing. Sp���k et al (14) ��v����g���� 768 adult MG patients and found that 112 patients (14.15%) also suffered from other autoimmune diseases. In the present study, one 12-year-old female p������ experienced repeated recurrence of bulging eyes over the first 3 ����� following treatment. The initial examination for AchR-Ab was negative, but was p�����v� �� ����������; ������g for ����������� ����b����� was also positive. Graves' ������� �� reportedly rare in patients with MG (0.2%), whereas 5-10% of patients with MG have autoimmune thyroid diseases (15) . Antithyroid antibodies are more common in OMG and report-���� ���� ������ �� A���� p������� (16) . In the patients in the p������ �����, ���������� G��v��' �p�������p���� was not as ������. It is difficult to ��������� when proptosis ��� p����� �pp���, b�� ����� ����b��� ����� ��� help with the ���g�����, p����������� in children with atypical clinical manifestations ��� �� definitive diagnosis. Therefore, routine testing for ����-thyroid antibodies and thyroid function should be performed and other autoimmune diseases should be considered.
Of the patients who were ��������� A��R-Ab-��g���v�, 53% b����� p�����v� �����g ��������� �� following relapse, which ��� b� � �������� �����g a different period of the same disease �� ��� b� ��� �� differ����� �� ����v����� �������� ��� associated with the level of antibody titers and differ����� �� ��������� �� v������ tissues and organs (17) . Dynamic follow-up ��� �������� ��� ����b��� p�����v��� rate in children with MG; however, as a causative factor, AchR-Ab was long-standing in ������� p�������, ���������g ���� ���g-���� ��������� ��� lower ��� ���k of recurrence.
It was previously demonstrated ����, �� �������� �� b���g A��R-Ab ��������, MG p����g������ ���� ��v��v�� ����� ����b����� �� ���������, ���� �� T����-Ab, which were �������� found to be highly relevant with thymoma-������� MG (MGT). T�� T����-Ab p�����v��� rate in MGT was as high as 80-90%, which is of high diagnostic value for MGT. The level of serum T����-Ab was ���� found to be significantly correlated with MGT severity and AchR-Ab levels. The detected positiv��� rate of Titin-Ab in the present group was 40% and the positive p������� were ���� p�����v� for A��R-Ab, ������g� ��� ���g��g ������� ��v����� �� �v������ of thymoma. However, follow-up of the Titin-Ab-positive patients was necessary, particularly for diagnosis by enhanced CT. Foreign studies have reported that positive RyR-Ab is associated with GMG, p����������� with severe oropharyngeal muscle weakness that often occurs �����g ���������� ������ (12); however, �� ���� ����������� was found in the 3 positive patients who were followed up. In this group, 71% of patients had abnormal CD series, with ��� majority displaying decreased CD4 + ��� CD8 + , ���������g ���� immune cells also play a role in the pathogenesis of MG.
MG �� ������� ����g���� �� ��� ������g ��� worsens �� ��� �v����g ��� p������� ��� �xp������� �����p���� p�������� in the later stages. Two patients with upper eyelid, limb and bulbar muscle involvement experienced sustained myasthenia. F���g�� ��� ���g ������g was ��g���v� ��� ��� p������� were diagnosed with brain stem encephalitis. Other p������� were misdiagnosed with oculomotor nerve palsy, muscular dystrophy, G�������-B���é ��������, ������������� ��������, ���������p-���� and other symptoms. These patients were all diagnosed by positive AchR-Ab and EMG and recovered during the follow-up after treatment; therefore, ��v���� differential diagnoses should be considered in the clinical setting. Early onset should also be distinguished from congenital myasthenic syndrome. Another 9 patients were had negative neostigmine test results, but the AchR-Ab were present or the results of the EMG were positive, ��� ������� treatment was effective. Therefore, acquired autoim-���� MG ������ ���� be considered.
Although the pathogenesis of MG is clear, the current�� �v����b�� ���������� ��� ��� ������-�� ����g��-specific. The ������������� ��� �������� ��������� ��������� ��� ��������� not uniform, including hormone measurements, course of treat-���� ��� ��������� of second-line drugs. Acetylcholinesterase inhibitors were suitable for all MG patients, except those underg���g ��������g�� ������, ��� ��� significantly reduce muscle weakness and impede AchR repair; therefore, ���� ������ ��� b� ���� �� � ���g�� �g��� in the long term. Many advocate the use of ������� �����p� �� ��� ����� ���g�� (18) �� p��v��� ����-������� ��������� weakness. Corticosteroids, which are the most commonly used first-line immunomodulatory therapy for MG, �x��� multiple effects on T-����, B-cell and macrophage function. Kupersmith (18) ��p����� ���� p��������� ��� ����� ��� reduce the incidence of GMG after >4 years of follow-up ��� effectively control recurrence.
The following advantages of methylprednisolone pulse therapy were observed: �) satisfactory effect in the short term, with rapidly ��p��v��g ���p����; ��) �b����� �� ������ �� ������-����� �������������� ����b���� ��� �� ��� ����� ���� ��� simplify ���������; ���) relatively few adverse reactions, effectively ���������� �����g ���p�����������; ��� �v) �b����� �� ������ �� ������ ������� as soon as possible and continue with outpatient observation and treatment. However, a retrospective analysis ��g�����g MG ������ ��������� ���� �� ��� b� ���������� with inappropriate methylprednisolone pulse therapy (19) . Our data ������������ that the average time to onset and duration of the maximum effect in the ������� pulse group was superior to the transitional reduction of ��� ���� p��������� g���p ��� ��� p���-dinium bromide neostigmine in combination with reduction of prednisone group. Except for the two MG patients who received �������� �����, ��� ��������g �������� ��� ��� �xp������� MG exacerbation or crisis. S������ ��������� of ����� �������� �������� �� ����� ����p��; a treatment duration of ≥2 years was ���������� more appropriate. In addition to Cushing'� facies, weight gain �����g the early stages of medication and high blood pressure �������� �� 1 patient, but there were �� ��v��� ��v���� ���g ��������� �� the majority of the patients who were ������������ ������� therapy. However, regular referrals to ophthalmology, blood glucose monitoring, blood pressure monitoring, a low-salt diet, use of cod liver oil supplements and monitoring of calcium ��� b��� ������� ��� �����������. If the illness recurs during ���������, ��� ������� ���� ��� b� �������� �� p��-��������� ��v���; ���������v���, cholinesterase inhibitors, IVIG, or other ��������pp�����v� �g���� ��� be added in the short-term if ��� manifestations are ��v���.
Azathioprine, which is the most common immunosuppres-���� ���� ���g-���� �� ����� MG �� �������� �� ���������������, was proven to be effective through randomized controlled trials. Cyclosporine A is the only treatment confirmed �� b� effective �� ��p��v��g �������� ���p���� ��� ���������g ����-A��R ����� ��v��� ���p���� �� � ������� g���p �� � ����������, ���b��-blind, controlled trial. In the Children's Hospital of Zhengzhou, cyclosporine A treatment was used for 1.5 years in children with repeated relapses with steroid-resistant or -��p������ �������, on the basis of observed ��v��� side effects with azathioprine, ��p���� �� the effectiveness of cyclosporine A treatment (20) in addition to our own experience with cyclosporine A and ��� lack of ��v��� adverse events with cyclosporine A ���������. Other clinica��� �pp���� ���g� ��� ��������� �������, ���� �� cyclophosphamide, mycophenolate mofetil, tacrolimus, plasmapheresis and thymectomy were also used. Recently, rituximab and antigen-specific plasma exchange were also used, but more �xp������� �� required. Thymectomy in pediatrics should be cautiously performed. In addition, the use of drugs that aggravate muscle weakness, such as aminoglycoside and macrolide ����b������, ������ b� �v�����; MG �x����b����� ��� ����� during surgery (21) . When the non-ionic contrast iohexol is used in enhanced CT, no aggravated weakness �� �b���v��.
In summary, MG in children is more common in China. OGM �� ������ ��� ����� ��� fewer patients who progressed to GMG, fewer patients with ���������� ��p������������ ��� a low incidence of thymoma. T�� �v����� p��g����� �� g���, with fewer neurological sequelae, ������g� v����� ��p������� should also be considered. The significance of integrated management, long-term follow-up, standardized treatment, education for children and parents and psychological support should be emphasized.
